{"id":892,"date":"2023-03-16T19:55:33","date_gmt":"2023-03-16T19:55:33","guid":{"rendered":"https:\/\/healthynewsusa.com\/?p=892"},"modified":"2023-03-16T19:55:33","modified_gmt":"2023-03-16T19:55:33","slug":"judging-the-abortion-pill-kaiser-health-news","status":"publish","type":"post","link":"https:\/\/healthynewsusa.com\/?p=892","title":{"rendered":"Judging the Abortion Pill | Kaiser Health News"},"content":{"rendered":"
\n
\n

\n\t\tThe Host\t<\/h3>\n
\n
\n
\n\t\t\t\n\t\t<\/div>\n<\/div><\/div>\n<\/div>\n

This week, the eyes of the nation are on Texas, where a federal judge who formerly worked for a conservative Christian advocacy group is set to decide whether the abortion pill mifepristone can stay on the market. Mifepristone is half of a two-pill regimen that now accounts for more than half of the abortions in the United States.<\/p>\n

Meanwhile, Novo Nordisk, another of the three large drug companies that dominate the market for diabetes treatments, has announced it will cut the price of many of its insulin products. Eli Lilly announced its cuts early this month. But the push for more affordable insulin from activists and members of Congress is not the only reason for the change: Because of quirks in the way the drug market works, cutting prices could actually save the companies money in the long run.<\/p>\n

This week\u2019s panelists are Julie Rovner of KHN, Jessie Hellmann of CQ Roll Call, Sarah Karlin-Smith of the Pink Sheet, and Alice Miranda Ollstein of Politico.<\/p>\n

Among the takeaways from this week\u2019s episode:<\/p>\n